{
    "id": 8573,
    "fullName": "NF2 S288*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "NF2 S288* results in a premature truncation of the Nf2 protein at amino acid 288 of 595 (UniProt.org). S288* results in reduced ability ot inhibit cell proliferation in culture (PMID: 31257748) and therefore, is predicted to lead to a loss of Nf2 protein function.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17214,
                    "pubMedId": 31257748,
                    "title": "Expression of NF2 Modulates the Progression of BRAFV600E Mutated Thyroid Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257748"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4771,
        "geneSymbol": "NF2",
        "terms": [
            "NF2",
            "ACN",
            "BANF",
            "SCH"
        ]
    },
    "variant": "S288*",
    "createDate": "07/02/2015",
    "updateDate": "01/15/2020",
    "referenceTranscriptCoordinates": {
        "id": 88824,
        "transcript": "NM_000268",
        "gDna": "chr22:g.29665042C>A",
        "cDna": "c.863C>A",
        "protein": "p.S288*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19809,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) and Lorbrena (lorlatinib) combination treatment inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 9223,
                "therapyName": "Lorlatinib + Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19811,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) and Lorbrena (lorlatinib) synergistically inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 9225,
                "therapyName": "Lorlatinib + Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19806,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vistusertib (AZD2014) inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 991,
                "therapyName": "Vistusertib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19804,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Lorbrena (lorlatinib) treatment resulted in oligo-progressive disease after 7 months of therapy in a patient with lung adenocarcinoma harboring EML4-ALK and an acquired NF2 splice site mutation (NM_000268.3:c.886-1G>A), NF2 S288* was detected in the biopsies at disease progression (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19810,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Afinitor (everolimus) and Lorbrena (lorlatinib) combination treatment inhibited growth of tumor cells derived from a patient with lung adenocarcinoma harboring EML4-ALK and acquired NF2 S288* and a NF2 splice site mutation (NM_000268.3:c.886-1G>A) in culture (PMID: 31585938).",
            "molecularProfile": {
                "id": 34534,
                "profileName": "EML4 - ALK NF2 S288* NF2 mut"
            },
            "therapy": {
                "id": 9224,
                "therapyName": "Everolimus + Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17546,
                    "pubMedId": 31585938,
                    "title": "Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31585938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 8471,
            "profileName": "NF2 S288*",
            "profileTreatmentApproaches": [
                {
                    "id": 11106,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "NF2 S288*"
                },
                {
                    "id": 11107,
                    "name": "Bevacizumab",
                    "profileName": "NF2 S288*"
                },
                {
                    "id": 11103,
                    "name": "mTOR Inhibitor",
                    "profileName": "NF2 S288*"
                },
                {
                    "id": 11104,
                    "name": "VEGFR Inhibitor (Pan)",
                    "profileName": "NF2 S288*"
                },
                {
                    "id": 11102,
                    "name": "EGFR Inhibitor (Pan)",
                    "profileName": "NF2 S288*"
                },
                {
                    "id": 11105,
                    "name": "PDGFR Inhibitor (Pan)",
                    "profileName": "NF2 S288*"
                }
            ]
        },
        {
            "id": 34534,
            "profileName": "EML4 - ALK NF2 S288* NF2 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 88823,
            "transcript": "NM_016418",
            "gDna": "chr22:g.29665042C>A",
            "cDna": "c.863C>A",
            "protein": "p.S288*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88824,
            "transcript": "NM_000268",
            "gDna": "chr22:g.29665042C>A",
            "cDna": "c.863C>A",
            "protein": "p.S288*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88822,
            "transcript": "NM_181832",
            "gDna": "chr22:g.29665042C>A",
            "cDna": "c.863C>A",
            "protein": "p.S288*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 88825,
            "transcript": "NM_181825",
            "gDna": "chr22:g.29665042C>A",
            "cDna": "c.863C>A",
            "protein": "p.S288*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}